2results about How to "Low hemolytic toxicity" patented technology

This invention discloses an antimicrobial 10-peptide, characterized by the sequence: w-k-r-w-r-r-w-w-r-r(dTrp-dLys-dArg-dTrp-dArg-dArg-dTrp-dTrp-dArg-dArg), where all amino acids are D-type amino acids. The antimicrobial peptide provided by this invention exhibits good antimicrobial activity against a variety of pathogenic bacteria. This antimicrobial peptide can be synthesized using the Fmoc solid-phase chemical method, which is easy to synthesize and exhibits good in vivo antimicrobial activity. This antimicrobial peptide exhibits broad-spectrum killing activity against multidrug-resistant Acinetobacter baumannii, carbapenem-resistant Pseudomonas aeruginosa, as well as standard strains of Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli, Enterobacter cloacae, methicillin-resistant Staphylococcus aureus, and Staphylococcus aureus. It has low hemolytic toxicity, and at low to medium concentrations (2 μg / mL to 32 μg / mL), the cell survival rate can reach more than 50%. It has no toxic effect on cells, good stability, strong operability, and low cost.

The invention belongs to the technical field of biology, and particularly relates to a scrota-derived antibacterial peptide and application thereof. The antibacterial peptide from the scrota is SPC-1 or SPC-2, and the antibacterial peptide from the scrota is SPC-2; wherein the amino acid sequence of the SPC-1 is as shown in a sequence table SEQ ID NO. 1, and the amino acid sequence of the SPC-2 is as shown in a sequence table SEQ ID NO. 2. The scrota antibacterial peptide provided by the invention is novel in amino acid sequence, has remarkable antibacterial activity on gram-negative bacteria and gram-positive bacteria, shows broad-spectrum antibacterial property, and has the advantages of low hemolysis toxicity, low cytotoxicity and high safety, and by virtue of the characteristics, the scrota antibacterial peptide shows excellent antibacterial value; and a new resource is provided for the development of antibacterial products against the human pathogenic bacteria.